MedTrace Logo

Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury

NCT03496545 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2021-06-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the antipyretic effect of bromocriptine in critically-ill patients with acute neurologic injury and fever from infectious and non-infectious etiologies.

Conditions

Interventions

DRUG

Bromocriptine 5 MG

Bromocriptine 5 mg every 4 hours PO/NG/FT

DRUG

Acetaminophen 650 MG

Acetaminophen 650 mg every 4 hours PO/NG/FT for 48 hours

Sponsors & Collaborators

Principal Investigators

  • Judy H Ch'ang, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-30
Primary Completion
2019-11-02
Completion
2019-11-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03496545 on ClinicalTrials.gov